📰 Engagers Tces News

Engagers Tces News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Engagers Tces. Real-time updates on events, politics, business and more.

Boehringer Ingelheim expands immunooncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

November 23, 2023

Boehringer Ingelheim today announced the acquisition of privatelyheld T3 Pharmaceuticals AG T3 Pharma a clinical stage Swiss biotech company for an amount of up to 450 million CHF.

Switzerland General Boehringer Ingelheim Engagers Tces Simon Ittig Michel Pairet Boehringer Ingelheim Venture Fund

Source: businesswireindia.com

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

November 23, 2023

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer ...

Switzerland General Michel Pairet Simon Ittig Boehringer Ingelheim Engagers Tces University Of Basel

Source: pharmiweb.com

Harpoon Therapeutics : Corporate Presentation – March 28, 2023

March 29, 2023

Spearheading Immunotherapies CORPORATE PRESENTATION MARCH 28, 2023 Nasdaq: HARP Forward-looking... | March 29, 2023

Engagers Tces Stage Of Development Exchange Commission Private Securities Litigation Stage Immuno Oncology Companydirectingt Cells Novelt Cell Engagers

Source: marketscreener.com

Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies | More News

June 3, 2022

Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies

Engagers Tces Biophotonics Bioimaging Damian Oconnell Cliver Wood I Boehringer Ingelheim Agency For Science

Source: pipelinereview.com

Community Scoop » Boehringer Ingelheim Enters Global Licensing Agreement To Develop And Commercialize Innovative Antibodies From A*STAR

June 3, 2022

Scoop Community provides New Zealand Community news and views

Rheinland Pfalz Engagers Tces Biophotonics Bioimaging Damian Oconnell Cliver Wood Agency For Science

Source: scoop.co.nz

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation